Towards individualized follow-up in adult acute myeloid leukemia in remission.
about
Advancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.Evaluation of BM cytomorphology after allo-SCT in patients with AML.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.Minimal residual disease in acute myeloid leukaemiaBack to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.A multigene array for measurable residual disease detection in AML patients undergoing SCTAzacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.FuGePrior: A novel gene fusion prioritization algorithm based on accurate fusion structure analysis in cancer RNA-seq samples.Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse.Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.New considerations in the design of clinical trials for the treatment of acute leukemia.Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Relapse assessment following allogeneic SCT in patients with MDS and AML.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Reduced-intensity conditioned allogeneic SCT in adults with AML.The emerging complexity of gene fusions in cancer.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients.Measurement of Residual Disease in Acute Myeloid Leukemia.Relapse kinetics in acute myeloid leukaemias withMLLtranslocations or partial tandem duplications within theMLLgene
P2860
Q28087291-352C47A5-4E9A-42D9-9019-6DA9D85CA4ECQ30234914-C6E2E277-282A-4A49-A3EE-7E4A9FFD18E7Q30318110-765FA539-E5C5-4DB7-8052-799FBB13E87EQ33832709-BCE1465A-8E9A-4C92-A9D8-7CB2A3088D46Q33877213-719FA047-3449-4CDE-86FD-C043F539FD66Q33931553-7FFE88C0-9ACF-4E53-9E38-A151F4DEB252Q34179265-8582D33A-0A66-4912-85C2-4F4E329DB9BAQ34380489-106B6F68-2F79-4CCB-8B92-2CC4784BD9B3Q35582360-7AF32AA7-9519-4135-AF14-6C41D456F137Q35835657-20E60EC7-4437-4D72-A7AA-974E32192A74Q36257816-999A44E5-3B20-480A-9FE1-A1692FF9EA85Q36444440-A1DCB932-1359-41E3-A3C8-A8D2A4345161Q36557537-29E6AE83-AB3D-4DE8-8F88-5BACD6F1BC54Q36641721-9C616905-FA31-46F6-969C-5AAF3EE84AF2Q37016999-4C8E0378-6A3C-477B-836C-7F95CCE6252EQ38022075-349D5875-D596-43E1-B435-3DC636000F31Q38028808-4904CFDB-51A6-420A-89BD-60F94479A632Q38199623-704EB572-3254-4F49-8152-CBD23D208C20Q38212956-F7C1A92E-C16E-41FB-AB54-E131CE014C26Q38366632-073F7F55-89FC-4BAB-BA1B-C560B158F9EFQ38496502-9E8DD14A-A8AC-46B2-8544-A6942BF9093BQ39132424-1EA862AD-72F1-4B65-8372-C5E3ECEFFDC7Q41553306-CC3A6AE8-DC59-4576-B85B-FC96901770ECQ41885481-BDBA4E3E-9E1A-4A36-92C8-56208F0486C0Q42930435-7B12158E-A8A7-4A0C-AD1B-D30C3E9A9570Q44059514-114EAECE-8ACE-4817-AEA7-FEEEB81AAC61Q45405674-72EDDA19-4922-451B-AF0E-9986AFCFE27DQ47156797-C27AB6C0-74F7-4F6E-B7C7-31C8F05BF66BQ50075132-7BF19664-E3ED-47AB-8B19-9A340B9B3377Q59194210-D232A889-F489-48FC-8568-F19A7B4E0650
P2860
Towards individualized follow-up in adult acute myeloid leukemia in remission.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Towards individualized follow-up in adult acute myeloid leukemia in remission.
@en
Towards individualized follow-up in adult acute myeloid leukemia in remission.
@nl
type
label
Towards individualized follow-up in adult acute myeloid leukemia in remission.
@en
Towards individualized follow-up in adult acute myeloid leukemia in remission.
@nl
prefLabel
Towards individualized follow-up in adult acute myeloid leukemia in remission.
@en
Towards individualized follow-up in adult acute myeloid leukemia in remission.
@nl
P1433
P1476
Towards individualized follow-up in adult acute myeloid leukemia in remission.
@en
P304
P356
10.1182/BLOOD-2010-09-303685
P407
P577
2010-11-19T00:00:00Z